NO996161L - En kontrollert frigjoerende formulering for tungt loeselige basiske legemidler - Google Patents

En kontrollert frigjoerende formulering for tungt loeselige basiske legemidler

Info

Publication number
NO996161L
NO996161L NO996161A NO996161A NO996161L NO 996161 L NO996161 L NO 996161L NO 996161 A NO996161 A NO 996161A NO 996161 A NO996161 A NO 996161A NO 996161 L NO996161 L NO 996161L
Authority
NO
Norway
Prior art keywords
controlled release
release formulation
soluble basic
basic drugs
heavily soluble
Prior art date
Application number
NO996161A
Other languages
English (en)
Other versions
NO310095B1 (no
NO996161D0 (no
Inventor
Neville W Broad
Alan F Carmody
Liam C Feely
Brian C Withers
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority to NO996161A priority Critical patent/NO310095B1/no
Publication of NO996161L publication Critical patent/NO996161L/no
Publication of NO996161D0 publication Critical patent/NO996161D0/no
Publication of NO310095B1 publication Critical patent/NO310095B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO996161A 1997-06-11 1999-12-13 En kontrollert frigjørende formulering for tungt løselige basiske legemidler NO310095B1 (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO996161A NO310095B1 (no) 1997-06-11 1999-12-13 En kontrollert frigjørende formulering for tungt løselige basiske legemidler

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1997/010705 WO1998056357A1 (en) 1995-12-19 1997-06-11 A controlled release formulation for poorly soluble basic drugs
NO996161A NO310095B1 (no) 1997-06-11 1999-12-13 En kontrollert frigjørende formulering for tungt løselige basiske legemidler

Publications (3)

Publication Number Publication Date
NO996161L true NO996161L (no) 1999-12-13
NO996161D0 NO996161D0 (no) 1999-12-13
NO310095B1 NO310095B1 (no) 2001-05-21

Family

ID=22261117

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996161A NO310095B1 (no) 1997-06-11 1999-12-13 En kontrollert frigjørende formulering for tungt løselige basiske legemidler

Country Status (4)

Country Link
NO (1) NO310095B1 (no)
SI (1) SI20108B (no)
SK (1) SK282427B6 (no)
WO (1) WO1998056357A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066174A2 (en) * 1999-04-29 2000-11-09 Russinsky Limited Compounds
EP1118333A1 (en) * 2000-01-18 2001-07-25 Eurand International S.P.A. Compositions with enhanced oral bioavailability
UA76967C2 (uk) * 2000-11-27 2006-10-16 Сандоз Аг Азитроміцин у формі моногідрату, фармацевтична композиція та спосіб його одержання
EP1492504A2 (en) * 2002-04-03 2005-01-05 Ranbaxy Laboratories, Ltd. Taste masked compositions of erythromycin a and derivatives thereof
SI21300A (sl) * 2002-10-08 2004-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtske formulacije z alginati
CN100336511C (zh) * 2002-11-15 2007-09-12 江苏豪森药业股份有限公司 口服罗红霉素控释制剂
PL1638529T3 (pl) * 2003-06-16 2017-03-31 Andrx Pharmaceuticals, Llc. Kompozycja doustna o przedłużonym uwalnianiu
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
JP2007513147A (ja) 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
EP3824296B1 (en) 2018-07-20 2026-04-01 Lipocine Inc. Oral pharmaceutical composition comprising testosterone tridecanoate and/or testosterone dodecanoate for treating liver diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60163823A (ja) * 1984-02-03 1985-08-26 Taisho Pharmaceut Co Ltd 経口投与製剤
DE3583799D1 (de) * 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs

Also Published As

Publication number Publication date
SK282427B6 (sk) 2002-01-07
NO310095B1 (no) 2001-05-21
SK161299A3 (en) 2000-05-16
SI20108A (sl) 2000-06-30
SI20108B (en) 2001-12-31
NO996161D0 (no) 1999-12-13
WO1998056357A1 (en) 1998-12-17

Similar Documents

Publication Publication Date Title
ZA9610110B (en) A controlled release formulation for poorly soluble basic drugs
NO996161D0 (no) En kontrollert frigjoerende formulering for tungt loeselige basiske legemidler
MA26576A1 (fr) Formulation pharmaceutique orale a liberation prolongee
MA26577A1 (fr) Formulation pharmaceutique orale a liberation pulsee
NO20000735D0 (no) Legemiddel leveringsanordning for vedvarende frigivelse
DE69812089D1 (de) Pharmazeutische omeprazol-formulierung
EE200000098A (et) Farmatseutiline kompositsioon piperidinoalkanooldekongestandi kombineerimiseks
EP1124543A4 (en) REGULATED RELEASE FORMULATION FOR WATER-SOLUBLE DRUGS
EP1008343A4 (en) QUICKLY SOLUBLE FILM-LIKE PREPARATION
EP0807433A4 (en) PREPARING WITH DELAYED RELEASE
EE200000361A (et) Seade ravimit sisaldava vedeliku manustamiseks
DE69904312D1 (de) Pharmazeutische aerosolformulierung
BR9607752B1 (pt) formulação farmacêutica de microcápsula de liberação controlada.
NO981008D0 (no) Farmasöytisk formulering
NO20002126L (no) Formulering med forlenget frigjøring
NO20001375L (no) Legemiddelformulering med kontrollert virkestoffrigivning
EP0976381A4 (en) DERMATOLOGICAL PREPARATION
PT868911E (pt) Formulacoes de rapamicina para administracao oral
EE9900545A (et) Farmatseutiline kompositsioon
AU5026599A (en) A wet granulation method for preparing a stable pharmaceutical formulation
ID30032A (id) Formulasi farmasi
DK0994697T3 (da) Rapamycinformuleringer til oral indgivelse
NO980072D0 (no) Opplösbar frigjöringsmekanisme for bevegelige skjöter
HRP970325B1 (en) Controlled release formulation for poorly soluble basic drugs
GB9724175D0 (en) A pharmaceutical formulation

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BGP PRODUCTS OPERATIONS GMBH, CH

MK1K Patent expired